Editorial is judgment in advance of the facts

BMJ (Online)

Volumn 340, Issue 7746, 2010, Pages 549-

  Finer, Nick ^a   Caterson, Ian ^a   Coutinho, Walmir ^a   Van Gaal, Luc ^a   Maggioni, Aldo ^a   Torp Pedersen, Christian ^a   Sharma, Arya ^a   James, Philip ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RIMONABANT; SIBUTRAMINE; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE;

BLOOD PRESSURE; EUROPE; HUMAN; HYPERTENSION; LETTER; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; WEIGHT REDUCTION; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG RECALL;

ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CYCLOBUTANES; HUMANS; OBESITY; SAFETY-BASED DRUG WITHDRAWALS;

EID: 77949380605     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c1346     Document Type: Letter

References (5)

1. Williams G. Withdrawal of sibutramine in Europe. BMJ 2010;340:c824. (9 February.)[Free Full Text]
2. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, et al; SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007;28:2915-23.[Abstract/Free Full Text]
3. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, et al; STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000;356:2119-25. [CrossRef][Web of Science][Medline]
4. Scottish Intercollegiate Guidelines Network. Management of obesity. Guideline No 115. February 2010. Available at: www.sign.ac.uk/guidelines/ fulltext/115/index.html.
5. Adan RA, Vanderschuren LJ, la Fleur SE. Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci 2008;29:208-17.[CrossRef] [Medline]